{"schemaVersion":1,"research":true,"symbol":"mdt","name":"Medtronic plc","topic":"moat","path":"/stock/mdt/moat","status":"published","version":10,"updatedAt":"2026-10-23T03:33:15.164Z","locked":false,"publicFairValue":false,"fairValue":null,"moat":{"verdict":"uncertain","summary":"Medtronic's proprietary devices, achieved regulatory clearances and long-lived implants support plausible intangible-asset and switching-cost advantages. The supplied passages do not establish durable competitive protection across its portfolio. Growth and committed purchases demonstrate demand, while procurement pressure and historical industry share shifts limit confidence in pricing discretion and resilience. Realized pricing cannot be isolated from the supplied results. MiniMed's completed separation also limits the relevance of historical consolidated performance to today's business.","advantages":[{"mechanism":"intangible_assets","claim":"Exclusive device technology and achieved regulatory clearances establish differentiated products and commercialization capabilities. Their ability to sustain an economic moat remains unproven.","durability":"BlueSync appears in both the 2024 and 2026 business disclosures, demonstrating continued deployment. However, the passages provide neither patent protection horizons nor sustained comparative clinical or market-share outcomes.","risks":"Patent expiry, competing technology, quality problems and procurement pressure require continuing innovation and regulatory execution. Historical industry share shifts show that incumbency can be disrupted.","invalidation":"The proposed advantage would weaken if equivalent competing products removed meaningful differentiation, regulatory or quality failures restricted commercialization, or successive launches failed to sustain demand.","competitors":[],"evidenceIds":["e1","e2","e3","e4"],"counterEvidenceIds":["e5","e6","e7"]},{"mechanism":"switching_costs","claim":"Long-lived implanted devices and device-linked monitoring plausibly create continuity costs within an existing patient relationship. Noncancellable minimum-purchase contracts establish a bounded commitment, without proving portfolio-wide customer lock-in.","durability":"Implant duration supports continuity during treatment, and disclosed purchase commitments extend beyond one year. Replacement loyalty, interoperability restrictions and physician switching costs are not quantified.","risks":"Continuity for an implanted patient need not protect future hospital purchasing or replacement decisions. Competitive tenders, clinical evidence and safety issues can redirect new demand.","invalidation":"This hypothesis would be undermined by easy migration of monitoring or treatment to alternatives, weak replacement loyalty, or declining committed purchases alongside sustained losses of repeat demand.","competitors":[],"evidenceIds":["e1","e8","e9","e10","e11"],"counterEvidenceIds":["e5","e7"]}],"evidence":[{"id":"e1","location":"2026 Form 10-K, Business: Azure pacemakers and exclusive BlueSync technology; filed June 18, 2026","sourceId":"filing-1","excerpt":"Azure pacemakers feature Medtronic-exclusive BlueSync technology, which enables automatic, secure wireless remote monitoring with increased device longevity."},{"id":"e2","location":"2024 Form 10-K, Business: Azure pacemakers and BlueSync technology; filed June 20, 2024","sourceId":"filing-3","excerpt":"Azure pacemakers feature Medtronic-exclusive BlueSync technology, which enables automatic, secure wireless remote monitoring with increased device longevity."},{"id":"e3","location":"FY26 results release: achieved Stealth AXiS regulatory clearances; filed June 3, 2026","sourceId":"filing-8","excerpt":"•Secured FDA Clearance for Spine, Cranial and ENT indications and CE Mark for Spine and Cranial indications for Stealth AXiS™ Surgical System"},{"id":"e4","location":"Q1 FY27 results release: Touch Surgery Aide FDA clearance; filed September 1, 2026","sourceId":"filing-7","excerpt":"•Announced FDA clearance for Touch Surgery™ Aide next generation computing platform"},{"id":"e5","location":"2025 Form 10-K, competition: historical industry market-share shifts; filed June 20, 2025","sourceId":"filing-2","excerpt":"Major shifts in industry market share have occurred in connection with product corrective actions, physician advisories, safety alerts, results of clinical trials to support superiority claims, and publications about our products, reflecting the importance of product quality, product efficacy and quality systems in the medical device industry."},{"id":"e6","location":"2026 Form 10-K, risk factors: patent expiry and protection limitations; filed June 18, 2026","sourceId":"filing-1","excerpt":"In addition, our patents will expire over time, our ability to protect novel business models is uncertain, and infringement may go undetected."},{"id":"e7","location":"2025 Form 10-K, competition: procurement, reimbursement and competitive pricing; filed June 20, 2025","sourceId":"filing-2","excerpt":"In the current environment of managed care, economically motivated \n10\nTable of Content\ncustomers, consolidation among healthcare providers, increased competition, declining reimbursement rates, and national and provincial tender pricing, competitively priced product offerings are essential to our business."},{"id":"e8","location":"2026 Form 10-K, product-liability risks: long-lived implanted devices; filed June 18, 2026","sourceId":"filing-1","excerpt":"In addition, many of our products are often used in intensive care settings with seriously ill patients, and some of the medical devices we manufacture and sell are designed to be implanted in the human body for long periods of time or indefinitely."},{"id":"e9","location":"Q1 FY27 Form 10-Q, revenue: noncancellable minimum-purchase contracts; filed September 3, 2026","sourceId":"filing-4","excerpt":"Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable, contracts with minimum purchase commitments."},{"id":"e10","location":"Q1 FY27 Form 10-Q, revenue: remaining obligations at July 31, 2026; filed September 3, 2026","sourceId":"filing-4","excerpt":"At July 31, 2026, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately $0.4 billion."},{"id":"e11","location":"Q1 FY27 Form 10-Q, revenue: expected recognition period for remaining obligations; filed September 3, 2026","sourceId":"filing-4","excerpt":"The Company expects to recognize revenue on the majority of these remaining performance obligations over the next three years."},{"id":"e12","location":"2025 Form 10-K, reimbursement and procurement cost controls; filed June 20, 2025","sourceId":"filing-2","excerpt":"Government programs, including Medicare and Medicaid, private healthcare insurance, managed-care plans, and volume-based procurement tenders in China, have attempted to control costs by limiting the amount of reimbursement they will pay for particular procedures or treatments, tying reimbursement to outcomes, shifting to population health management, and other mechanisms."},{"id":"e13","location":"FY26 results release: GAAP and non-GAAP operating-margin changes; filed June 3, 2026","sourceId":"filing-8","excerpt":"•FY26 operating margin was flat year-over-year; FY26 non-GAAP operating margin decreased 130 basis points, or 150 basis points constant currency"},{"id":"e14","location":"Q1 FY27 results release: GAAP operating profit and margin; filed September 1, 2026","sourceId":"filing-7","excerpt":"Q1 GAAP operating profit and operating margin were $1.764 billion and 18.1%, respectively, an increase of 22.1% and 120 basis points, respectively."},{"id":"e15","location":"Q1 FY27 results release: non-GAAP operating profit and margin; filed September 1, 2026","sourceId":"filing-7","excerpt":"As detailed in the financial schedules included at the end of the release, Q1 non-GAAP operating profit and operating margin were $2.316 billion and 23.7%, respectively, an increase of 14.9% and 10 basis points, respectively."},{"id":"e16","location":"Q1 FY27 results release: extra fiscal week qualification; filed September 1, 2026","sourceId":"filing-7","excerpt":"Results were impacted by the extra fiscal week, which occurred in Medtronic’s first quarter of FY27."},{"id":"e17","location":"Q1 FY27 results release: estimated extra-week organic-growth benefit; filed September 1, 2026","sourceId":"filing-7","excerpt":"The company estimates the impact of the extra week benefited Q1 organic growth by approximately $570 million."},{"id":"e18","location":"Q1 FY27 Form 10-Q, consolidation scope: MiniMed financial results included; filed September 3, 2026","sourceId":"filing-4","excerpt":"Due to the Company retaining a controlling financial interest, the unaudited condensed consolidated financial statements include the financial results of MiniMed."},{"id":"e19","location":"FY26 results release: FY2024–FY2026 operating cash flow, capital expenditure and free cash flow, in millions; filed June 3, 2026","sourceId":"filing-8","excerpt":"17\nMEDTRONIC PLC\nGAAP TO NON-GAAP RECONCILIATIONS(1)\n(Unaudited)\nFiscal Year\n(in millions)\n2026\n2025\n2024\nNet cash provided by operating activities\n$\n7,330 \n$\n7,044 \n$\n6,787 \nAdditions to property, plant, and equipment\n(1,904)\n(1,859)\n(1,587)\nFree Cash Flow(2)\n$\n5,426 \n$\n5,185 \n$\n5,200 \nSee description of non-GAAP financial measures contained in the press release dated June 3, 2026."},{"id":"e20","location":"FY26 results release: shareholder capital returns; filed June 3, 2026","sourceId":"filing-8","excerpt":"•Company returned $4.2 billion to shareholders in FY26"},{"id":"e21","location":"Q1 FY27 Form 10-Q, investing activities: acquisition-spending increase and investment sales; filed September 3, 2026","sourceId":"filing-4","excerpt":"The increase was primarily driven by an increase in acquisitions of $1.2 billion, partially offset by net sales of investments of $109 million."},{"id":"e22","location":"Q1 FY27 Form 10-Q, financing activities: short-term borrowing changes; filed September 3, 2026","sourceId":"filing-4","excerpt":"During the three months ended July 31, 2026, the Company had an increase of short-term borrowings of $812 million as compared to $649 million increase during the three months ended July 25, 2025."},{"id":"e23","location":"2026 proxy, compensation risk assessment: executive stock-ownership requirements; filed August 17, 2026","sourceId":"filing-9","excerpt":"•The NEOs are subject to stock ownership guidelines that require our CEO to maintain ownership of stock equal to six times annual base salary, and other NEOs to maintain ownership of stock equal to three times annual base salary."},{"id":"e24","location":"2026 proxy, compensation risk assessment: compliance as of August 1, 2026; filed August 17, 2026","sourceId":"filing-9","excerpt":"As of August 1, 2026, all NEOs are in compliance with the stock ownership and retention guidelines."},{"id":"e25","location":"2026 proxy, compensation risk assessment: recent appointees' ownership-threshold exceptions; filed August 17, 2026","sourceId":"filing-9","excerpt":"Mr. Piéton and Ms. Quinn have not yet reached their applicable ownership thresholds due to their recent appointments as executive officers, but each is in compliance with the policy’s retention requirements."},{"id":"e26","location":"2026 proxy: executive equity retention and adopted compensation-recovery policies; filed August 17, 2026","sourceId":"filing-9","excerpt":"Further, the Company does not provide excessive perquisites or benefits to our NEOs, requires each executive to retain significant portions of his or her equity compensation awards in support of our stock ownership guidelines, continues to follow a clawback policy that allows the Company to recapture equity compensation and other incentive awards paid to an executive who engages in misconduct, and has adopted a policy for recovery of erroneously awarded compensation in the event of an accounting restatement, in accordance with Exchange Act Rule 10D-1 and NYSE Rule 303A.14."},{"id":"e27","location":"2026 proxy: change-of-control compensation and replacement-award vesting conditions; filed August 17, 2026","sourceId":"filing-9","excerpt":"For example, the change of control policy does not include any excise tax gross-up provisions, and equity awards granted under the 2021 Medtronic plc Long Term Incentive Plan that are replaced in connection with a change of control do not vest on the occurrence of a change in control and instead vest only if a participant is involuntarily terminated with a limited period following the change of control."},{"id":"e28","location":"2026 proxy, corporate governance: actual director independence; filed August 17, 2026","sourceId":"filing-9","excerpt":"Geoff Martha is an employee and is not independent; the remaining directors are independent."},{"id":"e29","location":"2026 proxy, corporate governance: annual board, committee and director evaluations; filed August 17, 2026","sourceId":"filing-9","excerpt":"Board Performance Evaluations \nPursuant to the Company’s Governance Principles, the Board of Directors, all Committees, and each individual director undergo an annual performance self-evaluation process."},{"id":"e30","location":"October 2026 Form 8-K: actual advisory compensation-vote outcome; filed October 19, 2026","sourceId":"filing-10","excerpt":"The shareholders approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers."},{"id":"e31","location":"October 2026 Form 8-K: continued combined chairman and CEO roles; filed October 19, 2026","sourceId":"filing-10","excerpt":"Martha, who will continue to serve as the Company’s Chairman of the Board of Directors and Chief Executive Officer."},{"id":"e32","location":"October 2026 Form 8-K, Item 7.01: October 15 MiniMed separation announcement, read with continuation; filed October 19, 2026","sourceId":"filing-10","excerpt":"Regulation FD Disclosure\nOn October 15, 2026, the Company announced that the exchange offer relating to the separation of MiniMed Group, Inc."},{"id":"e33","location":"October 2026 Form 8-K, Item 7.01: continuation confirming exchange settlement and completed separation; filed October 19, 2026","sourceId":"filing-10","excerpt":"had settled and that the separation was complete."},{"id":"e34","location":"FY26 results release: worldwide reported, adjusted and organic revenue growth; filed June 3, 2026","sourceId":"filing-8","excerpt":"FY26 Financial Results \n•Medtronic reported FY26 worldwide revenue of $36.364 billion and adjusted revenue of $36.325 billion, an increase of 8.4% as reported and 5.8% on an organic basis."},{"id":"e35","location":"Q1 FY27 results release: worldwide reported and organic revenue growth; filed September 1, 2026","sourceId":"filing-7","excerpt":"Financial Results\nMedtronic reported Q1 worldwide revenue of $9.756 billion, an increase of 13.7% as reported and 13.7% on an organic basis."},{"id":"e36","location":"FY26 results release: operating-margin impacts from MiniMed Blackstone payment and tariffs; filed June 3, 2026","sourceId":"filing-8","excerpt":"The operating margin includes impacts of 45 basis points from the MiniMed Blackstone payment and 50 basis points from tariffs."}],"changes":["Retain the uncertain moat verdict; differentiation and treatment continuity remain plausible advantages without demonstrated portfolio-wide durability.","Change realized_pricing from 2 to null: the current catalog does not contain the previous analysis's favorable-pricing or historical realized-price-decrease evidence. Growth and margins do not isolate price.","Reassess management using current ownership requirements, adopted recovery policies, actual operating results and completed transactions. Do not carry forward unsupported claims about PSU payouts, missed incentive goals, Hugo clearance, proxy access or investment write-offs.","Assess all four moat criteria directly from current catalog evidence rather than leaving them ungraded because the overall verdict is uncertain."],"limitations":["The supplied passages do not identify named product-market competitors. Acquired companies, partners, lenders and compensation references are not established product competitors; competitor arrays therefore remain empty.","Product exclusivity and performance descriptions are issuer disclosures. Regulatory clearances establish achieved commercialization milestones, not comparative clinical superiority or durable economic protection.","No quantified replacement loyalty, customer retention, switching expense, market-share series, relevant patent expiry schedule or comparative unit-cost evidence is supplied.","Pricing outcomes and detailed contractual repricing rights are absent. Disclosed procurement constraints support a contractual-freedom assessment but do not establish actual price changes.","FY26 and Q1 FY27 consolidated results include MiniMed; separation was announced complete on October 15, 2026. Q1 also benefited from an extra fiscal week, limiting extrapolation to the current portfolio.","Source dates cited here retain the catalog's filed dateKind. Prior accepted analysis is comparison context only."],"qualityAssessments":[{"category":"moat","checks":[{"criterion":"structural_advantage","grade":2,"rationale":"Exclusive monitoring technology, achieved device clearances and long-lived implants establish differentiation and plausible continuity costs. They support a mixed structural assessment because the catalog does not show sustained comparative outcomes, replacement loyalty or a portfolio-wide barrier to competing products.","evidenceIds":["e1","e3","e4","e8","e5"]},{"criterion":"durability","grade":2,"rationale":"BlueSync's presence in the 2024 and 2026 disclosures demonstrates continuing deployment, while implants and multiyear purchase commitments support some persistence. Patent expiry and historical industry share shifts limit confidence. Continued product availability is weaker evidence than sustained economic protection.","evidenceIds":["e1","e2","e8","e9","e10","e11","e5","e6"]},{"criterion":"customer_dependency","grade":2,"rationale":"Implanted devices with remote monitoring support ongoing treatment relationships, and noncancellable minimum purchases establish some contractual dependence. The approximately $0.4 billion of remaining obligations at July 31, 2026 covers contracts originally lasting at least one year; it does not establish broad hospital or physician dependence.","evidenceIds":["e1","e8","e9","e10","e11"]},{"criterion":"erosion_resilience","grade":2,"rationale":"FY26 organic growth and new regulatory clearances demonstrate continued demand and product renewal despite a demanding competitive environment. Historical industry share shifts and procurement pressure temper that evidence. Aggregate growth does not establish share protection, and the historical consolidated scope includes MiniMed.","evidenceIds":["e3","e4","e34","e5","e7","e18"]}]},{"category":"pricing_power","checks":[{"criterion":"realized_pricing","grade":null,"rationale":"The catalog discloses revenue growth, margin changes and procurement pressure but does not isolate realized selling-price changes. Neither stronger sales nor stable margins distinguishes price from volume, mix, costs or fiscal-calendar effects. The previous analysis's pricing claims cannot supply missing current evidence.","evidenceIds":["e7","e13","e14","e15","e34","e35","e16","e17"]},{"criterion":"retention","grade":2,"rationale":"Long-lived implants, device-linked monitoring, minimum-purchase commitments and FY26 organic growth indirectly support continuing demand. These are mixed retention indicators: treatment continuity and outstanding commitments do not demonstrate renewal rates, replacement loyalty or resistance to competitive procurement.","evidenceIds":["e1","e8","e9","e10","e11","e34"]},{"criterion":"margin_resilience","grade":2,"rationale":"FY26 GAAP operating margin was flat while non-GAAP margin fell 130 basis points, with disclosed tariff and MiniMed payment impacts. Q1 FY27 subsequently improved both measures. This is mixed resilience, qualified by the extra fiscal week and MiniMed consolidation; pricing's contribution is unestablished.","evidenceIds":["e13","e14","e15","e16","e18","e36"]},{"criterion":"contractual_freedom","grade":1,"rationale":"The disclosed purchasing environment makes competitive pricing essential, with provider consolidation, tender pricing and reimbursement cost controls constraining discretion over terms. These business conditions support a weak grade. Exact repricing rights and contract-level concessions are absent, so the extent of constraint remains unquantified.","evidenceIds":["e7","e12"]}]},{"category":"strong_management","checks":[{"criterion":"capital_discipline","grade":2,"rationale":"FY26 operating cash flow of $7.330 billion funded $1.904 billion of capital expenditure, leaving $5.426 billion before shareholder returns of $4.2 billion. Q1 FY27 acquisition spending and short-term borrowing increased. Actual funding discipline is demonstrated, but acquisition returns and post-separation allocation outcomes remain unproven.","evidenceIds":["e19","e20","e21","e22"]},{"criterion":"incentive_alignment","grade":3,"rationale":"Actual ownership and retention compliance, salary-multiple ownership requirements, adopted clawbacks and conditional change-of-control vesting establish meaningful alignment mechanisms. Recent appointees have not reached ownership thresholds. These implemented safeguards support a strong grade without establishing exceptional realized pay-for-performance outcomes.","evidenceIds":["e23","e24","e25","e26","e27"]},{"criterion":"execution","grade":2,"rationale":"FY26 organic growth, achieved clearances and completed MiniMed separation demonstrate operating and transaction delivery. Q1 growth offers additional indirect evidence but benefited from an extra week. FY26 adjusted-margin contraction and the absence of demonstrated separation benefits keep execution mixed rather than exceptional.","evidenceIds":["e3","e4","e34","e35","e16","e17","e13","e32","e33"]},{"criterion":"governance","grade":3,"rationale":"All directors except the CEO are independent, annual board evaluations are disclosed, compensation-recovery policies are adopted, and shareholders actually approved compensation in an advisory vote. Combined chairman and CEO roles concentrate leadership. These safeguards support strong formal governance, with limited evidence of oversight effectiveness in difficult decisions.","evidenceIds":["e28","e29","e26","e30","e31"]}]}],"financialAssessments":[],"qualityPolicy":"quality-scores-3","sourcePolicy":"issuer-evidence-9","basisHash":"0dee37c559d118ec71292bd165e00786f11c778f12671c7abdb62fbebc66a61e","updatedAt":"2026-10-23T03:33:15.164Z","sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm","publishedAt":"2026-06-18","sha256":"350e017de4c8526b4d19cd547b6c3f997d1b8803e91ca17c20aa467b0050c977","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310325000091/mdt-20250425.htm","publishedAt":"2025-06-20","sha256":"e5f3fcba5ed70b28d635f13f35bbe889d575929a89ae577b6baea2e46a52c695","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310324000072/mdt-20240426.htm","publishedAt":"2024-06-20","sha256":"8956972ff1ed2abc20353dd6255cec010bd40d10a652f9872a7fd972ac625443","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-4","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/mdt-20260731.htm","publishedAt":"2026-09-03","sha256":"4e91f47aeca6b7714846653487869acc3d285a643536f14198f7f1badf9d62c5","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-5","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026011107/mdt-20260123.htm","publishedAt":"2026-02-24","sha256":"4a7a145be568fd561d2753bed0b1d186e07f3ba765bda4cd3cd0c9775adcf1a8","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-6","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026066291/exhibit991-statementdatedo.htm","publishedAt":"2026-10-19","sha256":"c69cd4b1dbae5f9cc1a41aef12d68df4774b43c0efee21b6befe9df8b72d0739","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-7","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026059697/exhibit991-fy27q1earningsr.htm","publishedAt":"2026-09-01","sha256":"5ae68bb31ef9480a91901b653d98aff2c7d8e8f5402d269a4a9450206212dab5","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-8","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026040034/exhibit991-fy26q4earningsr.htm","publishedAt":"2026-06-03","sha256":"a219f6053561f15459e528df68bef8bc807e2369cee96e42ad118c17130a3a28","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-9","url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310326000010/mdt-20260816.htm","publishedAt":"2026-08-17","sha256":"3b6427ba84ac1568ff2608bd4bdf51ea14a4c1d67e2d0b55b71a15794b600e08","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-10","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026066291/mdt-20261015.htm","publishedAt":"2026-10-19","sha256":"5a8ee1fd8bcc08576ddcb9edb44b4a449abc1659604ba4091cc4e908d0a790bb","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-11","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828025048375/mdt-20251101.htm","publishedAt":"2025-11-03","sha256":"c4b5126886ccb59527547c85bd08fdfebf175e3ebe1fb7a0e384447f970c5019","citationPolicy":"numeric-blocks-2","dateKind":"filed"}],"model":"gpt-6.1-sol","providerId":"codex:13612e980a08435c646b5ea23a20aa9220400858baf374c28b2b8e0d203c79fd","usage":{"input_tokens":84931,"cached_input_tokens":0,"cache_write_input_tokens":0,"output_tokens":4340,"reasoning_output_tokens":207},"basisSupplement":{"previousHash":"9c1553df4a04fffabccada96e9915df9e76b8fb9bd2fd6cbb23fa987326b198f","checkedAt":"2026-10-29T11:34:19.507Z","rule":"dated historical and empty core inputs only; known observations, prior evidence and research date retained"}},"signals":[{"period":"2022","end":"2022-04-29","values":{"gross_margin":67.9827052957142,"operating_margin":18.153127564223947,"roic":7.153709870143043,"fcf_margin":18.866376317616613,"sbc_revenue":1.1329924887963139},"issues":{"software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roiic":"Invested capital did not increase versus the prior year. ROIIC requires a positive increase.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2023","end":"2023-04-28","values":{"gross_margin":65.67393601690844,"operating_margin":17.564927786851122,"roic":5.242749292106942,"fcf_margin":14.666794760944054,"sbc_revenue":1.1368367118198994},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","pfcf_growth":"TTM FCF per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2024","end":"2024-04-26","values":{"gross_margin":65.34420961562229,"operating_margin":15.89420343591645,"roic":5.299960333001177,"fcf_margin":16.0672351996045,"sbc_revenue":1.21431219873934},"issues":{"peg":"TTM earnings per diluted share growth is zero or negative; a growth-adjusted multiple requires positive growth.","software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roiic":"Invested capital did not increase versus the prior year. ROIIC requires a positive increase.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2025","end":"2025-04-25","values":{"gross_margin":65.31591973044696,"operating_margin":17.756507737722515,"roic":6.676730105693926,"fcf_margin":15.460536124280647,"sbc_revenue":1.279184184631899},"issues":{"software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}},{"period":"2026","end":"2026-04-24","values":{"gross_margin":65.01759982400176,"operating_margin":17.78407215927841,"roic":6.7684473045225655,"fcf_margin":14.921350786492136,"sbc_revenue":1.2567374326256737},"issues":{"software_capex":"Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.","roic_wacc":"Enter a WACC assumption from 0 to 100%."}}],"sources":[{"id":"filing-1","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm","publishedAt":"2026-06-18","sha256":"350e017de4c8526b4d19cd547b6c3f997d1b8803e91ca17c20aa467b0050c977","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-2","url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310325000091/mdt-20250425.htm","publishedAt":"2025-06-20","sha256":"e5f3fcba5ed70b28d635f13f35bbe889d575929a89ae577b6baea2e46a52c695","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-3","url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310324000072/mdt-20240426.htm","publishedAt":"2024-06-20","sha256":"8956972ff1ed2abc20353dd6255cec010bd40d10a652f9872a7fd972ac625443","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-4","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/mdt-20260731.htm","publishedAt":"2026-09-03","sha256":"4e91f47aeca6b7714846653487869acc3d285a643536f14198f7f1badf9d62c5","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-5","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026011107/mdt-20260123.htm","publishedAt":"2026-02-24","sha256":"4a7a145be568fd561d2753bed0b1d186e07f3ba765bda4cd3cd0c9775adcf1a8","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-6","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026066291/exhibit991-statementdatedo.htm","publishedAt":"2026-10-19","sha256":"c69cd4b1dbae5f9cc1a41aef12d68df4774b43c0efee21b6befe9df8b72d0739","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-7","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026059697/exhibit991-fy27q1earningsr.htm","publishedAt":"2026-09-01","sha256":"5ae68bb31ef9480a91901b653d98aff2c7d8e8f5402d269a4a9450206212dab5","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-8","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026040034/exhibit991-fy26q4earningsr.htm","publishedAt":"2026-06-03","sha256":"a219f6053561f15459e528df68bef8bc807e2369cee96e42ad118c17130a3a28","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-9","url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310326000010/mdt-20260816.htm","publishedAt":"2026-08-17","sha256":"3b6427ba84ac1568ff2608bd4bdf51ea14a4c1d67e2d0b55b71a15794b600e08","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-10","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828026066291/mdt-20261015.htm","publishedAt":"2026-10-19","sha256":"5a8ee1fd8bcc08576ddcb9edb44b4a449abc1659604ba4091cc4e908d0a790bb","citationPolicy":"numeric-blocks-2","dateKind":"filed"},{"id":"filing-11","url":"https://www.sec.gov/Archives/edgar/data/1613103/000162828025048375/mdt-20251101.htm","publishedAt":"2025-11-03","sha256":"c4b5126886ccb59527547c85bd08fdfebf175e3ebe1fb7a0e384447f970c5019","citationPolicy":"numeric-blocks-2","dateKind":"filed"}],"history":[{"version":10,"updatedAt":"2026-10-31T09:05:44.078Z","verdict":"uncertain","value":null},{"version":9,"updatedAt":"2026-10-28T03:35:08.167Z","verdict":"uncertain","value":null},{"version":8,"updatedAt":"2026-10-24T20:23:11.515Z","verdict":"uncertain","value":null},{"version":7,"updatedAt":"2026-10-23T13:12:13.141Z","verdict":"uncertain","value":null},{"version":6,"updatedAt":"2026-10-22T20:01:07.958Z","verdict":"uncertain","value":null},{"version":5,"updatedAt":"2026-10-19T18:33:29.802Z","verdict":"uncertain","value":null},{"version":4,"updatedAt":"2026-10-19T13:57:15.039Z","verdict":"uncertain","value":null},{"version":3,"updatedAt":"2026-10-18T16:35:43.872Z","verdict":"uncertain","value":null},{"version":2,"updatedAt":"2026-10-18T02:27:49.793Z","verdict":"uncertain","value":null},{"version":1,"updatedAt":"2026-10-18T02:18:02.026Z","verdict":null,"value":null}],"hasRequested":false,"requestStatus":"completed","researchIssue":null,"archivedMoat":null,"scope":"supported_catalog"}